capmatinib,pembrolizumab
novartis,incyte,merck
['sclc', 'capmatinib', 'lcsm,(-blcsm)', 'nsclc', 'pembro']
capmatinib plus pembrolizumab does not provide clinical benefit in met unselected, pd-l1-high expressing nsclc #asco22 #lcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.